This document is an excerpt from the EUR-Lex website
Document 62011CO0574
Order of the Court (Eighth Chamber) of 9 February 2012.#Novartis AG v Actavis Deutschland GmbH & Co KG and Actavis Ltd.#Reference for a preliminary ruling — Landgericht Düsseldorf — Interpretation of Articles 4 and 5 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009 L 152, p. 1) — Scope of the certificate — Protection solely of medicinal products consisting only of the protected active ingredient or protection extended to medicinal products consisting of the protected active ingredient in combination with another active ingredient.#The first subparagraph of Article 104(3) of the Rules of Procedure — Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Articles 4 and 5 — Sole active ingredient for which such a certificate is granted — Scope of protection — Medicinal product containing more than one active ingredient, including the active ingredient which is the subject of a certificate.#Case C‑574/11.
Rješenje Suda (osmo vijeće) od 2012. veljača 09.
Novartis AG protiv Actavis Deutschland GmbH & Co KG i Actavis Ltd.
Zahtjev za prethodnu odluku, podnesena po Landgericht Düsseldorf.
Predmet C-574/11.
Rješenje Suda (osmo vijeće) od 2012. veljača 09.
Novartis AG protiv Actavis Deutschland GmbH & Co KG i Actavis Ltd.
Zahtjev za prethodnu odluku, podnesena po Landgericht Düsseldorf.
Predmet C-574/11.
Court reports – general – 'Information on unpublished decisions' section
ECLI identifier: ECLI:EU:C:2012:68
- Date of document:
- 09/02/2012
- Date lodged:
- 16/11/2011
- Author:
- Sud
- Country or organisation from which the request originates:
- Njemačka
- Form:
- Rješenje
- Authentic language:
- njemački
- Type of procedure:
- Prethodno pitanje
- Judge-Rapporteur:
- Toader
- Advocate General:
- Trstenjak
- National court:
-
*A9* Landgericht Düsseldorf, Beschluss vom 08/11/2011 (4 b O 66/11)
- Treaty:
- Ugovor o funkcioniranju Europske unije
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Interprets 32009R0469 A04
- Interprets 32009R0469 A05
- Instruments cited in case law:
-
- 31991Q0704(02)-A104P3L1: N 16
- 32009R0469-A01: N 3
- 32009R0469-A02: N 4
- 32009R0469-A03: N 5
- 32009R0469-A04: N 1 6 15 17 - 21
- 32009R0469-A05: N 1 7 15 17 - 21
- 62010CJ0322: N 18
- 62010CJ0422: N 18
- 62010CO0630: N 18
- 62011CO0006: N 18
- Notes relating to the decision:
-
- 1. Seitz, Claudia: Arzneimittelrecht: Schutzumfang eines ergänzenden Schutzzertifikats, Europäische Zeitschrift für Wirtschaftsrecht 2012 p.432-433
- Subject matter:
- Case law directory code:
-
Order of the Court (Eighth Chamber) of 9 February 2012 — Novartis v Actavis Deutschland and Actavis
(Case C‑574/11)
The first subparagraph of Article 104(3) of the Rules of Procedure — Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Articles 4 and 5 — Sole active ingredient for which such a certificate is granted — Scope of protection — Medicinal product containing more than one active ingredient, including the active ingredient which is the subject of a certificate
Approximation of laws — Uniform legislation — Industrial and commercial property — Patent right — Supplementary protection certificate for medicinal products — Protection conferred by the certificate — Scope (European Parliament and Council Regulation No 469/2009, Arts 4 and 5) (see paras 18-21, operative part)
Re:
| Reference for a preliminary ruling — Landgericht Düsseldorf — Interpretation of Articles 4 and 5 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009 L 152, p. 1) — Scope of the certificate — Protection solely of medicinal products consisting only of the protected active ingredient or protection extended to medicinal products consisting of the protected active ingredient in combination with another active ingredient. |
Operative part
Articles 4 and 5 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that, where a ‘product’ consisting of an active ingredient was protected by a basic patent and the holder of that patent was able to rely on the protection conferred by that patent for that ‘product’ in order to oppose the marketing of a medicinal product containing that active ingredient in combination with one or more other active ingredients, a supplementary protection certificate granted for that ‘product’ enables its holder, after the basic patent has expired, to oppose the marketing by a third party of a medicinal product containing that product for a use of the ‘product’, as a medicinal product, which was authorised before that certificate expired.
